The role of academia in early drug development: from basic research to industrial translation Contribuciones de la academia al desarrollo temprano de fármacos: de la ciencia básica a la aplicación industrial
Article Sidebar
Publicado
nov 3, 2026
##plugins.pubIds.doi.readerDisplayName##
https://doi.org/10.30878/ces.v32n0a63
Main Article Content
Sarah Eliuth Ochoa Hugo
http://orcid.org/0000-0003-2964-4208
http://orcid.org/0000-0003-2964-4208
Resumen
This article examines the role of academia in early-stage drug development, from basic research to industrial translation. Through a targeted bibliographic review, it describes strategies such as phenotypic, virtual, and fragment-based screening, rational design, computational modeling, in silico pharmacokinetics, and preclinical testing. The analysis identifies methodological gaps, lack of standardization, and insufficient collaboration with industry as key barriers to translational progress. It concludes that early engagement between academia and industry, along with improved coordination of scientific efforts, is essential to accelerate therapeutic innovation and translate research findings into tangible public health benefits.
Article Details
Como citar
OCHOA HUGO, Sarah Eliuth.
The role of academia in early drug development: from basic research to industrial translation.
CIENCIA ergo-sum, [S.l.], v. 33, nov. 2026.
ISSN 2395-8782.
Disponible en: <https://cienciaergosum.uaemex.mx/article/view/26042>. Fecha de acceso: 07 nov. 2026
doi: https://doi.org/10.30878/ces.v32n0a63.
Sección
Ciencias de la salud humana
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
Citas
Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., Orhan, I. E., Banach, M., Rollinger, J. M., Barreca, D., Weckwerth, W., Bauer, R.,... & Supuran, C. T. (2021). Natural products in drug discovery: advances and opportunities. Nature Reviews Drug Discovery, 20, 200-216. https://doi.org/10.1038/s41573-020-00114-z
Atkinson, A. J., Colburn, W. A., DeGruttola, V. G., DeMets, D. L., Downing, G. J., Hoth, D. F., Oates, J. A., Peck, C. C., Schooley, R. T., Spilker, B. A., Woodcock, J., & Zeger, S. L. (2001). Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework. Clinical Pharmacology and Therapeutics, 69(3), 89-95. https://doi.org/10.1067/MCP.2001.113989
Bajorath, J. (2002). Integration of virtual and high-throughput screening. Nature Reviews Drug Discovery, 1(11), 882-894. https://doi.org/10.1038/nrd941
Barnes, E. C., Kumar, R., & Davis, R. A. (2016). The use of isolated natural products as scaffolds for the generation of chemically diverse screening libraries for drug discovery. Natural Product Reports, 33(3), 372-381. https://doi.org/10.1039/C5NP00121H
Beevers, C., Uno, Y., Meurer, K., Hamada, S., Hashimoto, K., Kirkland, D., LeBaron, M. J., Le Curieux, F., Le Hegarat, L., Martus, H., & Witt, K. L. (2023). in vivo Genotoxicity Testing Strategies: Report from the 8th International Workshop on Genotoxicity Testing (IWGT). Environmental and Molecular Mutagenesis. https://doi.org/10.1002/EM.22578
BigSCAPE (2023, july). BiG-SCAPE/CORASON pipeline. BiG-SCAPE-CORASON. https://bigscape-corason.secondarymetabolites.org/index.html
Blay, V., Tolani, B., Ho, S. P., & Arkin, M. R. (2020a). High-Throughput Screening: today’s biochemical and cell-based approaches. Drug Discovery Today, 25(10), 1807-1821. https://doi.org/10.1016/j.drudis.2020.07.024
Blay, V., Tolani, B., Ho, S. P., & Arkin, M. R. (2020b). High-Throughput Screening: today’s biochemical and cell-based approaches. Drug Discovery Today, 25(10), 1807-1821. https://doi.org/10.1016/j.drudis.2020.07.024
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012). Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nature reviews. Drug discovery, 11(12), 909-922. https://doi.org/10.1038/nrd3845
Caroline dos Santos Picanço, L., Ozela, P. F., De Fátima de Brito Brito, M., Pinheiro, A. A., Padilha, E. C., Braga, F. S., Henrique Tomich de Paula da Silva, C., Breno Rodrigues dos Santos, C., Rosa, J. M., & Izabel da Silva Hage-Melim, L. (2018). Alzheimer’s Disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment. Current Medicinal Chemistry, 25, 3141-3159. https://doi.org/10.2174/09298673236661612131
ChEMBL. (2022, november 27). ChEMBL Database. https://www.ebi.ac.uk/chembl/
Cheng, F., Ma, Y., Uzzi, B., & Loscalzo, J. (2020). Importance of scientific collaboration in contemporary drug discovery and development: a detailed network analysis. BMC Biology, 18(1), 1-9. https://doi.org/10.1186/S12915-020-00868-3/TABLES/1
Cowling, B. S., & Thielemans, L. (2020). Translational medicine in neuromuscular disorders: From academia to industry. DMM Disease Models and Mechanisms, 13(2). https://doi.org/10.1242/DMM.041434/225259
DrugCentral. (2023, June 20). DrugCentral 2023. https://drugcentral.org/
DrugBank Team. (2024). The Collaboration Between Industry and Academia in Drug Development. DrugBank. https://blog.drugbank.com/the-collaboration-between-industry-and-academia-in-drug-development/
Ellinger, B., & Gribbon, P. (2016). Risk mitigation in academic drug discovery. Expert Opinion on Drug Discovery, 11(4), 333-336. https://doi.org/10.1517/17460441.2016.1152257
Finegold, D., & Moser, A. (2006). Ethical decision-making in bioscience firms. Nature Biotechnology, 24(3), 285-290. https://doi.org/10.1038/nbt0306-285
Flobak, Å., Skånland, S. S., Hovig, E., Taskén, K., & Russnes, H. G. (2022). Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models. TIPS - Trends in Pharmacological Sciences, 43(11), 973-985. https://doi.org/10.1016/j.tips.2022.08.009
Giordano, D., Biancaniello, C., Argenio, M. A., & Facchiano, A. (2022). Drug Design by Pharmacophore and Virtual Screening Approach. Pharmaceuticals (Basel, Switzerland), 15(5), 646. https://doi.org/10.3390/ph15050646
GTEx Portal. (2023, June 20). Bulk Tissue RNA-Seq Sample Info. https://gtexportal.org/home/tissue/Thyroid
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., Shorte, S. L., Turcatti, G., von Schantz, C., & Carragher, N. O. (2016). Screening out irrelevant cell-based models of disease. Nature reviews. Drug discovery, 15(11), 751-769. https://doi.org/10.1038/nrd.2016.175
IDG (Illuminating the Druggable Genome). (2023, June 20). Illuminating the Druggable Genome. Page Home. https://druggablegenome.net/
IUPHAR/BPS Guide to PHARMACOLOGY. (2023). IUPHAR (International Union of Basic and Clinical Pharmacology)/British Pharmacological Society (BPS) Guide to PHARMACOLOGY Page Home. https://www.guidetopharmacology.org/
Kim S. (2016). Getting the most out of PubChem for virtual screening. Expert opinion on drug discovery, 11(9), 843-855. https://doi.org/10.1080/17460441.2016.1216967
Kirchmair, J., Göller, A. H., Lang, D., Kunze, J., Testa, B., Wilson, I. D., Glen, R. C., & Schneider, G. (2015). Predicting drug metabolism: experiment and/or computation?. Nature reviews. Drug discovery, 14(6), 387-404. https://doi.org/10.1038/nrd4581
Koçak, M., & Akçalı, Z. (2025). The published role of artificial intelligence in drug discovery and development: a bibliometric and social network analysis from 1990 to 2023. Journal of Cheminformatics, 17(1), 1-24. https://doi.org/10.1186/S13321-025-00988-4
Konski, A. F., & Foley & Lardner LLP. (2025). Unlocking the Future of Medicine: The Role of AI in Drug Discovery. National Law Review. https://natlawreview.com/article/unlocking-future-medicine-role-ai-drug-discovery
Kraus, V. B. (2018). Biomarkers as drug development tools: discovery, validation, qualification and use. Nature Reviews. Rheumatology, 14(6), 354-362. https://doi.org/10.1038/S41584-018-0005-9
Lewis, D. (2025, may 8). A Powerful Pairing: Academia-Industry Collaborations for Pharmaceutical Innovation. World Pharma Today. https://www.worldpharmatoday.com/articles/a-powerful-pairing-academia-industry-collaborations-for-pharmaceutical-innovation/
Lilly Investors. (2025, May 9). Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation. https://investor.lilly.com/news-releases/news-release-details/lilly-plans-expand-purdue-university-collaboration-250-million
Liotta, D., & Painter, G. (2018). Academic Drug Development: The DRIVE Model. ACS Medicinal Chemistry Letters, 9(5), 403-407. https://doi.org/10.1021/ACSMEDCHEMLETT.8B00124
Lipinski C. A. (2016). Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Advanced drug delivery reviews, 101, 34-41. https://doi.org/10.1016/j.addr.2016.04.029
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews, 46(1-3), 3-26. https://doi.org/10.1016/s0169-409x(00)00129-0
Liu, M., & Quinn, R. J. (2019). Fragment-based screening with natural products for novel anti-parasitic disease drug discovery. Expert opinion on drug discovery, 14(12), 1283-1295. https://doi.org/10.1080/17460441.2019.1653849
Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A. K., Côté, S., Shoichet, B. K., & Urban, L. (2012). Large-scale prediction and testing of drug activity on side-effect targets. Nature, 486(7403), 361-367. https://doi.org/10.1038/nature11159
Mackie, J. E., Taylor, A. D., Finegold, D. L., Daar, A. S., & Singer, P. A. (2006). Lessons on ethical decision making from the bioscience industry. PLoS Medicine, 3(5), e129. https://doi.org/10.1371/journal.pmed.0030129
Mayr, L. M., & Bojanic, D. (2009). Novel trends in high-throughput screening. Current opinion in pharmacology, 9(5), 580-588. https://doi.org/10.1016/j.coph.2009.08.004
Mendez, D., Gaulton, A., Bento, A. P., Chambers, J., De Veij, M., Félix, E., Magariños, M. P., Mosquera, J. F., Mutowo, P.,... & Leach, A. R. (2019). ChEMBL: Towards direct deposition of bioassay data. Nucleic Acids Research, 47(D1), D930-D940. https://doi.org/10.1093/nar/gky1075
Mitragotri, S., Burke, P. A., & Langer, R. (2014). Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nature reviews. Drug discovery, 13(9), 655-672. https://doi.org/10.1038/nrd4363
Mitsopoulos, C., Di Micco, P., Fernandez, E. V., Dolciami, D., Holt, E., Mica, I. L., Coker, E. A., Tym, J. E.,... & Al-Lazikani, B. (2021). CanSAR: Update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research, 49(D1), D1074-D1082. https://doi.org/10.1093/NAR/GKAA1059
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017). Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nature reviews. Drug discovery, 16(8), 531-543. https://doi.org/10.1038/nrd.2017.111
Muller, P. Y., & Milton, M. N. (2012). The determination and interpretation of the therapeutic index in drug development. Nature reviews. Drug discovery, 11(10), 751-761. https://doi.org/10.1038/nrd3801
National Library of Medicine. (2023, November 14). Learn About Studies. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/study-basics/learn-about-studies#q
NIP (Norwegian Institute of Public Health). (2023, June 20). ATC/DDD Index. https://www.whocc.no/atc_ddd_index/
NCATS (National Center for Advancing Translational Sciences). (2023, June 20). NCATS Pharmaceutical Collection. https://ncats.nih.gov/expertise/preclinical/npc
Nussbaumer, P., & Klebl, B. (2015). Professional translational research: A new hybrid paradigm in early drug discovery. Future Medicinal Chemistry, 7(14), 1879-1889. https://doi.org/10.4155/fmc.15.124
Ocana, A., Pandiella, A., Privat, C., Bravo, I., Luengo-Oroz, M., Amir, E., & Gyorffy, B. (2025). Integrating artificial intelligence in drug discovery and early drug development: a transformative approach. Biomarker Research, 13(1), 1-12. https://doi.org/10.1186/s40364-025-00758-2
Ohlson, S., & Duong-Thi, M. D. (2018). Fragment screening for drug leads by weak affinity chromatography (WAC-MS). Methods (San Diego, Calif.), 146, 26-38. https://doi.org/10.1016/j.ymeth.2018.01.011
Passini, E., Zhou, X., Trovato, C., Britton, O. J., Bueno-Orovio, A., & Rodriguez, B. (2021). The virtual assay software for human in silico drug trials to augment drug cardiac testing. Journal of Computational Science, 52. https://doi.org/10.1016/j.jocs.2020.101202
Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013). Validating therapeutic targets through human genetics. Nature reviews. Drug discovery, 12(8), 581-594. https://doi.org/10.1038/nrd4051
Prinz, F., Schlange, T., & Asadullah, K. (2011). Believe it or not: how much can we rely on published data on potential drug targets? Nature Reviews. Drug Discovery, 10(9), 712-713. https://doi.org/10.1038/NRD3439-C1
PubMed. (2022, November 27). Page Home. https://pubmed.ncbi.nlm.nih.gov/
Ramadan, Q., Perinelli, D. R., Orian, L., & Baratchi, S. (2023). Editorial: Innovative approaches in drug discovery and development. Frontiers in Medical Technology, 5, 1206088. https://doi.org/10.3389/FMEDT.2023.1206088/BIBTEX
Seidel, T., Wieder, O., Garon, A., & Langer, T. (2020). Applications of the Pharmacophore Concept in Natural Product inspired Drug Design. Molecular informatics, 39(11), e2000059. https://doi.org/10.1002/minf.202000059
Shamoo, A. E., & Resnik, D. B. (2022b). Collaboration within Academia and with Industry. In Responsible Conduct of Research (pp. 83-105). https://doi.org/10.1093/OSO/9780197547090.003.0004
Tong, H., Phan, N. V. T., Nguyen, T. T., Nguyen, D. V., Vo, N. S., & Le, L. (2021). Review on Databases and Bioinformatic Approaches on Pharmacogenomics of Adverse Drug Reactions. Pharmacogenomics and personalized medicine, 14, 61–75. https://doi.org/10.2147/PGPM.S290781
Van Campen, L. E., Poplazarova, T., Therasse, D. G., Turik, M., Kelman, A., Rossetti, A., Chang, C., Stern, K. N., & Fortson, W. (2021). Considerations for applying bioethics norms to a biopharmaceutical industry setting. BMC Medical Ethics, 22(1), 1-11. https://doi.org/10.1186/S12910-021-00600-Y/FIGURES/2
Whitebread, S., Dumotier, B., Armstrong, D., Fekete, A., Chen, S., Hartmann, A., Muller, P. Y., & Urban, L. (2016). Secondary pharmacology: screening and interpretation of off-target activities - focus on translation. Drug discovery today, 21(8), 1232-1242. https://doi.org/10.1016/j.drudis.2016.04.021
WHO (World Health Organization). (2023, June 20). Health products policy and standards. International Nonproprietary Names Programme and Classification of Medical Products. https://www.who.int/teams/health-product-and-policy-standards/inn
Willett P. (2006). Similarity-based virtual screening using 2D fingerprints. Drug discovery today, 11(23-24), 1046-1053. https://doi.org/10.1016/j.drudis.2006.10.005
Yu, B., Lu, X., & Chang, J. (2024). Multidisciplinary Training for Fostering Next-Generation Medicinal Chemists. Journal of Medicinal Chemistry, 67(209). https://doi.org/10.1021/acs.jmedchem.4c02316
Zhang, J. H., Chung, T. D. Y., & Oldenburg, K. R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. Journal of Biomolecular Screening, 4(2). https://doi.org/10.1177/108705719900400206
Atkinson, A. J., Colburn, W. A., DeGruttola, V. G., DeMets, D. L., Downing, G. J., Hoth, D. F., Oates, J. A., Peck, C. C., Schooley, R. T., Spilker, B. A., Woodcock, J., & Zeger, S. L. (2001). Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework. Clinical Pharmacology and Therapeutics, 69(3), 89-95. https://doi.org/10.1067/MCP.2001.113989
Bajorath, J. (2002). Integration of virtual and high-throughput screening. Nature Reviews Drug Discovery, 1(11), 882-894. https://doi.org/10.1038/nrd941
Barnes, E. C., Kumar, R., & Davis, R. A. (2016). The use of isolated natural products as scaffolds for the generation of chemically diverse screening libraries for drug discovery. Natural Product Reports, 33(3), 372-381. https://doi.org/10.1039/C5NP00121H
Beevers, C., Uno, Y., Meurer, K., Hamada, S., Hashimoto, K., Kirkland, D., LeBaron, M. J., Le Curieux, F., Le Hegarat, L., Martus, H., & Witt, K. L. (2023). in vivo Genotoxicity Testing Strategies: Report from the 8th International Workshop on Genotoxicity Testing (IWGT). Environmental and Molecular Mutagenesis. https://doi.org/10.1002/EM.22578
BigSCAPE (2023, july). BiG-SCAPE/CORASON pipeline. BiG-SCAPE-CORASON. https://bigscape-corason.secondarymetabolites.org/index.html
Blay, V., Tolani, B., Ho, S. P., & Arkin, M. R. (2020a). High-Throughput Screening: today’s biochemical and cell-based approaches. Drug Discovery Today, 25(10), 1807-1821. https://doi.org/10.1016/j.drudis.2020.07.024
Blay, V., Tolani, B., Ho, S. P., & Arkin, M. R. (2020b). High-Throughput Screening: today’s biochemical and cell-based approaches. Drug Discovery Today, 25(10), 1807-1821. https://doi.org/10.1016/j.drudis.2020.07.024
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012). Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nature reviews. Drug discovery, 11(12), 909-922. https://doi.org/10.1038/nrd3845
Caroline dos Santos Picanço, L., Ozela, P. F., De Fátima de Brito Brito, M., Pinheiro, A. A., Padilha, E. C., Braga, F. S., Henrique Tomich de Paula da Silva, C., Breno Rodrigues dos Santos, C., Rosa, J. M., & Izabel da Silva Hage-Melim, L. (2018). Alzheimer’s Disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment. Current Medicinal Chemistry, 25, 3141-3159. https://doi.org/10.2174/09298673236661612131
ChEMBL. (2022, november 27). ChEMBL Database. https://www.ebi.ac.uk/chembl/
Cheng, F., Ma, Y., Uzzi, B., & Loscalzo, J. (2020). Importance of scientific collaboration in contemporary drug discovery and development: a detailed network analysis. BMC Biology, 18(1), 1-9. https://doi.org/10.1186/S12915-020-00868-3/TABLES/1
Cowling, B. S., & Thielemans, L. (2020). Translational medicine in neuromuscular disorders: From academia to industry. DMM Disease Models and Mechanisms, 13(2). https://doi.org/10.1242/DMM.041434/225259
DrugCentral. (2023, June 20). DrugCentral 2023. https://drugcentral.org/
DrugBank Team. (2024). The Collaboration Between Industry and Academia in Drug Development. DrugBank. https://blog.drugbank.com/the-collaboration-between-industry-and-academia-in-drug-development/
Ellinger, B., & Gribbon, P. (2016). Risk mitigation in academic drug discovery. Expert Opinion on Drug Discovery, 11(4), 333-336. https://doi.org/10.1517/17460441.2016.1152257
Finegold, D., & Moser, A. (2006). Ethical decision-making in bioscience firms. Nature Biotechnology, 24(3), 285-290. https://doi.org/10.1038/nbt0306-285
Flobak, Å., Skånland, S. S., Hovig, E., Taskén, K., & Russnes, H. G. (2022). Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models. TIPS - Trends in Pharmacological Sciences, 43(11), 973-985. https://doi.org/10.1016/j.tips.2022.08.009
Giordano, D., Biancaniello, C., Argenio, M. A., & Facchiano, A. (2022). Drug Design by Pharmacophore and Virtual Screening Approach. Pharmaceuticals (Basel, Switzerland), 15(5), 646. https://doi.org/10.3390/ph15050646
GTEx Portal. (2023, June 20). Bulk Tissue RNA-Seq Sample Info. https://gtexportal.org/home/tissue/Thyroid
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., Shorte, S. L., Turcatti, G., von Schantz, C., & Carragher, N. O. (2016). Screening out irrelevant cell-based models of disease. Nature reviews. Drug discovery, 15(11), 751-769. https://doi.org/10.1038/nrd.2016.175
IDG (Illuminating the Druggable Genome). (2023, June 20). Illuminating the Druggable Genome. Page Home. https://druggablegenome.net/
IUPHAR/BPS Guide to PHARMACOLOGY. (2023). IUPHAR (International Union of Basic and Clinical Pharmacology)/British Pharmacological Society (BPS) Guide to PHARMACOLOGY Page Home. https://www.guidetopharmacology.org/
Kim S. (2016). Getting the most out of PubChem for virtual screening. Expert opinion on drug discovery, 11(9), 843-855. https://doi.org/10.1080/17460441.2016.1216967
Kirchmair, J., Göller, A. H., Lang, D., Kunze, J., Testa, B., Wilson, I. D., Glen, R. C., & Schneider, G. (2015). Predicting drug metabolism: experiment and/or computation?. Nature reviews. Drug discovery, 14(6), 387-404. https://doi.org/10.1038/nrd4581
Koçak, M., & Akçalı, Z. (2025). The published role of artificial intelligence in drug discovery and development: a bibliometric and social network analysis from 1990 to 2023. Journal of Cheminformatics, 17(1), 1-24. https://doi.org/10.1186/S13321-025-00988-4
Konski, A. F., & Foley & Lardner LLP. (2025). Unlocking the Future of Medicine: The Role of AI in Drug Discovery. National Law Review. https://natlawreview.com/article/unlocking-future-medicine-role-ai-drug-discovery
Kraus, V. B. (2018). Biomarkers as drug development tools: discovery, validation, qualification and use. Nature Reviews. Rheumatology, 14(6), 354-362. https://doi.org/10.1038/S41584-018-0005-9
Lewis, D. (2025, may 8). A Powerful Pairing: Academia-Industry Collaborations for Pharmaceutical Innovation. World Pharma Today. https://www.worldpharmatoday.com/articles/a-powerful-pairing-academia-industry-collaborations-for-pharmaceutical-innovation/
Lilly Investors. (2025, May 9). Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation. https://investor.lilly.com/news-releases/news-release-details/lilly-plans-expand-purdue-university-collaboration-250-million
Liotta, D., & Painter, G. (2018). Academic Drug Development: The DRIVE Model. ACS Medicinal Chemistry Letters, 9(5), 403-407. https://doi.org/10.1021/ACSMEDCHEMLETT.8B00124
Lipinski C. A. (2016). Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Advanced drug delivery reviews, 101, 34-41. https://doi.org/10.1016/j.addr.2016.04.029
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews, 46(1-3), 3-26. https://doi.org/10.1016/s0169-409x(00)00129-0
Liu, M., & Quinn, R. J. (2019). Fragment-based screening with natural products for novel anti-parasitic disease drug discovery. Expert opinion on drug discovery, 14(12), 1283-1295. https://doi.org/10.1080/17460441.2019.1653849
Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A. K., Côté, S., Shoichet, B. K., & Urban, L. (2012). Large-scale prediction and testing of drug activity on side-effect targets. Nature, 486(7403), 361-367. https://doi.org/10.1038/nature11159
Mackie, J. E., Taylor, A. D., Finegold, D. L., Daar, A. S., & Singer, P. A. (2006). Lessons on ethical decision making from the bioscience industry. PLoS Medicine, 3(5), e129. https://doi.org/10.1371/journal.pmed.0030129
Mayr, L. M., & Bojanic, D. (2009). Novel trends in high-throughput screening. Current opinion in pharmacology, 9(5), 580-588. https://doi.org/10.1016/j.coph.2009.08.004
Mendez, D., Gaulton, A., Bento, A. P., Chambers, J., De Veij, M., Félix, E., Magariños, M. P., Mosquera, J. F., Mutowo, P.,... & Leach, A. R. (2019). ChEMBL: Towards direct deposition of bioassay data. Nucleic Acids Research, 47(D1), D930-D940. https://doi.org/10.1093/nar/gky1075
Mitragotri, S., Burke, P. A., & Langer, R. (2014). Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nature reviews. Drug discovery, 13(9), 655-672. https://doi.org/10.1038/nrd4363
Mitsopoulos, C., Di Micco, P., Fernandez, E. V., Dolciami, D., Holt, E., Mica, I. L., Coker, E. A., Tym, J. E.,... & Al-Lazikani, B. (2021). CanSAR: Update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research, 49(D1), D1074-D1082. https://doi.org/10.1093/NAR/GKAA1059
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017). Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nature reviews. Drug discovery, 16(8), 531-543. https://doi.org/10.1038/nrd.2017.111
Muller, P. Y., & Milton, M. N. (2012). The determination and interpretation of the therapeutic index in drug development. Nature reviews. Drug discovery, 11(10), 751-761. https://doi.org/10.1038/nrd3801
National Library of Medicine. (2023, November 14). Learn About Studies. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/study-basics/learn-about-studies#q
NIP (Norwegian Institute of Public Health). (2023, June 20). ATC/DDD Index. https://www.whocc.no/atc_ddd_index/
NCATS (National Center for Advancing Translational Sciences). (2023, June 20). NCATS Pharmaceutical Collection. https://ncats.nih.gov/expertise/preclinical/npc
Nussbaumer, P., & Klebl, B. (2015). Professional translational research: A new hybrid paradigm in early drug discovery. Future Medicinal Chemistry, 7(14), 1879-1889. https://doi.org/10.4155/fmc.15.124
Ocana, A., Pandiella, A., Privat, C., Bravo, I., Luengo-Oroz, M., Amir, E., & Gyorffy, B. (2025). Integrating artificial intelligence in drug discovery and early drug development: a transformative approach. Biomarker Research, 13(1), 1-12. https://doi.org/10.1186/s40364-025-00758-2
Ohlson, S., & Duong-Thi, M. D. (2018). Fragment screening for drug leads by weak affinity chromatography (WAC-MS). Methods (San Diego, Calif.), 146, 26-38. https://doi.org/10.1016/j.ymeth.2018.01.011
Passini, E., Zhou, X., Trovato, C., Britton, O. J., Bueno-Orovio, A., & Rodriguez, B. (2021). The virtual assay software for human in silico drug trials to augment drug cardiac testing. Journal of Computational Science, 52. https://doi.org/10.1016/j.jocs.2020.101202
Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013). Validating therapeutic targets through human genetics. Nature reviews. Drug discovery, 12(8), 581-594. https://doi.org/10.1038/nrd4051
Prinz, F., Schlange, T., & Asadullah, K. (2011). Believe it or not: how much can we rely on published data on potential drug targets? Nature Reviews. Drug Discovery, 10(9), 712-713. https://doi.org/10.1038/NRD3439-C1
PubMed. (2022, November 27). Page Home. https://pubmed.ncbi.nlm.nih.gov/
Ramadan, Q., Perinelli, D. R., Orian, L., & Baratchi, S. (2023). Editorial: Innovative approaches in drug discovery and development. Frontiers in Medical Technology, 5, 1206088. https://doi.org/10.3389/FMEDT.2023.1206088/BIBTEX
Seidel, T., Wieder, O., Garon, A., & Langer, T. (2020). Applications of the Pharmacophore Concept in Natural Product inspired Drug Design. Molecular informatics, 39(11), e2000059. https://doi.org/10.1002/minf.202000059
Shamoo, A. E., & Resnik, D. B. (2022b). Collaboration within Academia and with Industry. In Responsible Conduct of Research (pp. 83-105). https://doi.org/10.1093/OSO/9780197547090.003.0004
Tong, H., Phan, N. V. T., Nguyen, T. T., Nguyen, D. V., Vo, N. S., & Le, L. (2021). Review on Databases and Bioinformatic Approaches on Pharmacogenomics of Adverse Drug Reactions. Pharmacogenomics and personalized medicine, 14, 61–75. https://doi.org/10.2147/PGPM.S290781
Van Campen, L. E., Poplazarova, T., Therasse, D. G., Turik, M., Kelman, A., Rossetti, A., Chang, C., Stern, K. N., & Fortson, W. (2021). Considerations for applying bioethics norms to a biopharmaceutical industry setting. BMC Medical Ethics, 22(1), 1-11. https://doi.org/10.1186/S12910-021-00600-Y/FIGURES/2
Whitebread, S., Dumotier, B., Armstrong, D., Fekete, A., Chen, S., Hartmann, A., Muller, P. Y., & Urban, L. (2016). Secondary pharmacology: screening and interpretation of off-target activities - focus on translation. Drug discovery today, 21(8), 1232-1242. https://doi.org/10.1016/j.drudis.2016.04.021
WHO (World Health Organization). (2023, June 20). Health products policy and standards. International Nonproprietary Names Programme and Classification of Medical Products. https://www.who.int/teams/health-product-and-policy-standards/inn
Willett P. (2006). Similarity-based virtual screening using 2D fingerprints. Drug discovery today, 11(23-24), 1046-1053. https://doi.org/10.1016/j.drudis.2006.10.005
Yu, B., Lu, X., & Chang, J. (2024). Multidisciplinary Training for Fostering Next-Generation Medicinal Chemists. Journal of Medicinal Chemistry, 67(209). https://doi.org/10.1021/acs.jmedchem.4c02316
Zhang, J. H., Chung, T. D. Y., & Oldenburg, K. R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. Journal of Biomolecular Screening, 4(2). https://doi.org/10.1177/108705719900400206